Trial Profile
The Effects of the Rivastigmine Patch on Attention and Behavior in Parkinson's Disease With Dementia (PDD).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Apr 2014
Price :
$35
*
At a glance
- Drugs Rivastigmine (Primary)
- Indications Dementia
- Focus Therapeutic Use
- 14 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Aug 2010 Planned end date changed from 1 Apr 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
- 03 Dec 2009 Actual end date (November 2009) added as reported by ClinicalTrials.gov.